Latest Breaking News On - Multi luminance shape discrimination test - Page 1 : comparemela.com

Nanoscope Therapeutics Announces Presentation of Key Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa at the ARVO Annual Meeting

Nanoscope Therapeutics Announces Presentation of Key Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa at the ARVO Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Beverly hillsUnited statesDavid boyerPsulagna bhattacharyaSamarendra mohantyNanoscope therapeutics incDrug administrationVitreous associates medical groupPrnewswire nanoscope therapeutics incTherapeutics incMulti characteristic opsinMulti luminancey mobility testMulti luminance shape discrimination testBest corrected visual acuityRetina vitreous associates medical groupNanoscope clinical advisory board

Nanoscope Therapeutics Announces Presentation of Key Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa at the ARVO Annual Meeting

100% (18/18) MCO-010 patients experienced a clinically meaningful improvement in vision-guided mobility (MLYMT), near-field object recognition (MLSDT) or.

Beverly hillsUnited statesDavid boyerPsulagna bhattacharyaSamarendra mohantyNanoscope therapeutics incVitreous associates medical group in beverly hillsDrug administrationPrnewswire nanoscope therapeutics incTherapeutics incMulti characteristic opsinMulti luminancey mobility testMulti luminance shape discrimination testBest corrected visual acuityRetina vitreous associates medical groupNanoscope clinical advisory board

Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa

/PRNewswire/ Nanoscope Therapeutics Inc., today announced topline results from the Phase 2b multicenter, randomized, double-masked, sham-controlled RESTORE.

United statesNanoscope therapeutics incDrug administrationPrnewswire nanoscope therapeutics incTherapeutics incMulti characteristic opsinMulti luminancey mobility testMulti luminance shape discrimination testBest corrected visual acuityAbout retinitisRetinal ganglion cellsNanoscope therapeutics